Healthcare

Lung Disease Therapeutics Market Size To Cross USD 146.1 Bn By 2032

The global lung disease therapeutics market size accounted for US$ 81.2 Bn in 2022 and is projected to reach around USD 146.1 Bn by 2032, growing at a CAGR of 6.04% from 2023 to 2032.

Lung Disease Therapeutics Market Size 2023 To 2032

Report Summary

The global lung disease therapeutics market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the lung disease therapeutics market across the globe.

A comprehensive estimate on the lung disease therapeutics market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of lung disease therapeutics during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2927

Lung Disease Therapeutics Market Report Scope

Report Coverage Details
Market Size in 2023 USD 86.11 Billion
Market Size by 2032 USD 146.1 Billion
Growth Rate from 2023 to 2032 CAGR of 6.04%
Largest Market North America
Fastest Growing Market Asia Pacific
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered By Disease Type, By Drug Class, By Molecule Type, By Distribution Channel, and By Treatment Type
Regions Covered North America, Europe, Asia-Pacific, Latin America and Middle East & Africa

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized lung disease therapeutics market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read: High Performance Alloys Market Size To Cross USD 16.7 Bn By 2032

Lung Disease Therapeutics Market Players

The report includes the profiles of key lung disease therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

  • Johnson & Johnson
  • Amgen Inc.
  • AstraZeneca
  • Boehringer Ingelheim
  • Pfizer Inc.
  • Allergan Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Hoffmann-La Roche
  • Merck & Co
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie, Inc.
  • Novartis AG

Market Segmentation

By Disease Type

  • Asthma
  • Lung Cancer
  • Chronic Obstructive Pulmonary Disease (COPD)

By Drug Class

  • Corticosteroids
  • Bronchodilator
  • Antimicrobial
  • Alkylating Agents
  • Mucolytics

By Molecule Type

  • Small molecules
  • Biologics

By Treatment Type

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Radiation Therapy

By Distribution Channel

  • Online
  • Hospital
  • Retail

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Lung Disease Therapeutics Market 

5.1. COVID-19 Landscape: Lung Disease Therapeutics Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Lung Disease Therapeutics Market, By Disease Type

8.1. Lung Disease Therapeutics Market, by Disease Type, 2023-2032

8.1.1. Asthma

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Lung Cancer

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Chronic Obstructive Pulmonary Disease (COPD)

8.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Lung Disease Therapeutics Market, By Drug Class

9.1. Lung Disease Therapeutics Market, by Drug Class, 2023-2032

9.1.1. Corticosteroids

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Bronchodilator

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Antimicrobial

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Alkylating Agents

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Mucolytics

9.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Lung Disease Therapeutics Market, By Molecule Type 

10.1. Lung Disease Therapeutics Market, by Molecule Type, 2023-2032

10.1.1. Small molecules

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Biologics

10.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Lung Disease Therapeutics Market, By Treatment Type

11.1. Lung Disease Therapeutics Market, by Treatment Type, 2023-2032

11.1.1. Chemotherapy

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Immunotherapy

11.1.2.1. Market Revenue and Forecast (2020-2032)

11.1.3. Targeted Therapy

11.1.3.1. Market Revenue and Forecast (2020-2032)

11.1.4. Radiation Therapy

11.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Lung Disease Therapeutics Market, By Distribution Channel

12.1. Lung Disease Therapeutics Market, by Distribution Channel, 2023-2032

12.1.1. Online

12.1.1.1. Market Revenue and Forecast (2020-2032)

12.1.2. Hospital

12.1.2.1. Market Revenue and Forecast (2020-2032)

12.1.3. Retail

12.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 13. Global Lung Disease Therapeutics Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.1.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.1.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.1.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.1.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.1.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.1.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.1.6.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.1.6.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.1.7.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.1.7.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.1.7.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.1.7.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.2.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.2.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.2.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.2.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.2.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.2.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.2.7. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.2.8. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.2.9.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.2.9.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.2.10. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.2.11. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.2.12.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.2.12.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.2.12.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.2.13. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.2.14.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.2.14.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.2.14.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.2.15. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.3.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.3.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.3.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.3.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.3.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.3.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.3.6.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.3.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.3.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.3.8.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.3.8.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.3.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.3.10.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.3.10.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.3.10.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.3.11.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.3.11.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.3.11.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.4.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.4.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.4.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.4.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.4.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.4.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.4.6.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.4.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.4.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.4.8.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.4.8.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.4.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.4.10.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.4.10.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.4.10.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.4.11.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.4.11.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.4.11.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.5.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.5.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.5.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.5.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.5.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.5.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.5.6.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.5.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Disease Type (2020-2032)

13.5.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)

13.5.8.3. Market Revenue and Forecast, by Molecule Type (2020-2032)

13.5.8.4. Market Revenue and Forecast, by Treatment Type (2020-2032)

13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)

Chapter 14. Company Profiles

14.1. Johnson & Johnson

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Amgen Inc.

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. AstraZeneca

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Boehringer Ingelheim

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Pfizer Inc.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Allergan Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Bristol-Myers Squibb Company

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Eli Lilly and Company

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Hoffmann-La Roche

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Merck & Co

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com

Show More

Related Articles

Back to top button